세계의 T세포 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for T-Cell Therapies Market is presumed to reach the market size of nearly USD 29.51 BN by 2030 from USD 2.48 BN in 2022 with a CAGR of 36.28% under the study period 2023 - 2030.

T-cell therapies involve the use of T cells, a type of white blood cell, to treat various medical conditions, particularly certain types of cancers and immune-related disorders. T-cells are crucial in the immune system as these recognize and eliminate abnormal or infected cells. T-cell therapies harness and enhance the body's natural defense mechanisms to target and destroy specific cells.

MARKET DYNAMICS

The T-cell therapies market is driven by the revolutionary potential of these therapies, particularly in cancer treatment. The increasing cancer prevalence and the demand for more precise and effective treatments propel the adoption of T-cell therapies, such as CAR-T cell therapy. Advancements in biotechnology and genetic engineering play a crucial role, enabling the genetic modification of T cells for enhanced targeting of cancer cells. Positive clinical outcomes and demonstrated efficacy contribute to growing confidence among healthcare professionals and patients, further fostering the market's expansion. Collaborations and investments in research and development accelerate progress, leading to the development of new and improved T-cell therapies. Regulatory approvals and supportive frameworks ensure accessibility and commercialization, reinforcing the market's growth trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of t-cell therapies. The growth and trends of t-cell therapies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the t-cell therapies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

• CART-Cell Therapy
• T Cell Receptor (TCR)-Based
• Tumor Infiltrating Lymphocytes (TIL)-Based

By Indication

• Hematologic Malignancies (Lymphoma, Leukemia, Myeloma)
• Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others)
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the T-Cell Therapies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the T-Cell Therapies market include Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . T-CELL THERAPIES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapy Type
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY THERAPY TYPE

• 5.1 Overview by Therapy Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Therapy Type
• 5.4 CAR T-cell Therapy Historic and Forecast Sales by Regions
• 5.5 T Cell Receptor (TCR)-based Historic and Forecast Sales by Regions
• 5.6 Tumor Infiltrating Lymphocytes (TIL)-based Historic and Forecast Sales by Regions

6 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY INDICATION

• 6.1 Overview by Indication
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Indication
• 6.4 Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Historic and Forecast Sales by Regions
• 6.5 Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Historic and Forecast Sales by Regions
• 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE T-CELL THERAPIES COMPANIES

• 8.1. T-Cell Therapies Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF T-CELL THERAPIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Novartis AG
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Merck KGaA
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Gilead Sciences Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. TCR2 Therapeutics Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Bluebird Bio Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Sorrento Therapeutics
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Fate Therapeutics
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Amgen
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Celgene Corporation
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies